Results 171 to 180 of about 4,829,888 (359)

Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents

open access: yesMolecules
American trypanosomiasis or Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects approximately 6–7 million people worldwide. However, its pharmacological treatment causes several uncomfortable side effects, causing patients’ treatment ...
Rogelio Gómez-Escobedo   +9 more
doaj   +1 more source

Dietary Supplement Labeling: Cognitive Biases, Market Manipulation & Consumer Choice [PDF]

open access: yes, 2014
There exists increasing concern that the Dietary Supplements Health and Education Act (DSHEA) has proven ineffective. Much of the concern regards the disparity in legislative treatment between dietary supplements, foods, and pharmaceutical drugs. Namely,
McCann, Michael
core   +1 more source

A Tri‐Culture Heart‐on‐a‐Chip Platform With iPSC‐Derived Cardiac Cells for Predictive Cardiotoxicity Testing

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents the first entirely isogenic heart‐on‐chip, unifying cardiomyocytes, fibroblasts, and endothelial cells from a single iPSC source. The platform reveals a critical biological insight: the endothelium actively shields cardiac tissue from drug‐induced toxicity, challenging the predictive accuracy of conventional, avascular models for ...
Karine Tadevosyan   +12 more
wiley   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

open access: yesAdvanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang   +4 more
wiley   +1 more source

A Representative Survey of M.S. Patients on Attitudes toward the Benefits and Risks of Drug Therapy [PDF]

open access: yes, 2006
Background: Although M.S. patients face significant trade-offs between risks and benefits of drug therapy, little is known of their attitudes toward these risks and benefits.
John E. Calfee
core  

CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads

open access: yesAdvanced Healthcare Materials, EarlyView.
In this paper researchers introduce CORE LNPs, a new class of lipid nanoparticles engineered to redirect mRNA expression away from the liver and into the spleen, a key immune organ. By combining chemical design with computational tools, they created cholesterol analogs that enable precise spleen‐targeted expression, providing greater applications for ...
Eshan A. Narasipura   +4 more
wiley   +1 more source

Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration

open access: yesAdvanced Healthcare Materials, EarlyView.
Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu   +4 more
wiley   +1 more source

Animal Drugs @ FDA [PDF]

open access: yesJournal of the Medical Library Association : JMLA, 2009
openaire   +1 more source

Engineering Resatorvid‐Loaded Sub‐Microgels of Epigallocatechin‐3‐gallate/Hyaluronic Acid to Treat Acute Lung Injury

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents HAEP@Res sub‐microgels as a lung‐targeted delivery system integrating antioxidant activity with anti‐inflammatory therapy. The sub‐microgels demonstrate excellent biocompatibility, efficiently scavenge intracellular ROS, and downregulate pro‐inflammatory cytokines and genes in a Bleo‐induced ALI mouse model. These findings highlight
Bo Liu   +10 more
wiley   +1 more source

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

open access: yesAdvanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy